DOCSLIB.ORG

PDF (Guidelines for ATC Classification and DDD Assignment)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
PDF (Guidelines for ATC Classification and DDD Assignment) Guidelines for ATC classification and DDD assignment 2018 ISSN 1726-4898 ISBN 978-82-8082-896-5 Suggested citation: WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment 2018. Oslo, Norway, 2017. © Copyright WHO Collaborating Centre for Drug Statistics Methodology, Oslo, Norway. Use of all or parts of the material requires reference to the WHO Collaborating Centre for Drug Statistics Methodology. Copying and distribution for commercial purposes is not allowed. Changing or manipulating the material is not allowed. Guidelines for ATC classification and DDD assignment 21st edition WHO Collaborating Centre for Drug Statistics Methodology Norwegian Institute of Public Health P.O.Box 4404 Nydalen N-0403 Oslo Norway Telephone: (47) 21078160 E-mail: [email protected] Website: www.whocc.no Previous editions: 1990: Guidelines for ATC classification1) 1991: Guidelines for DDD1) 1993: Guidelines for ATC classification 1993: Guidelines for DDD 1996: Guidelines for ATC classification and DDD assignment 1998: Guidelines for ATC classification and DDD assignment 2000: Guidelines for ATC classification and DDD assignment 2001: Guidelines for ATC classification and DDD assignment 2002: Guidelines for ATC classification and DDD assignment 2003: Guidelines for ATC classification and DDD assignment 2004: Guidelines for ATC classification and DDD assignment 2005: Guidelines for ATC classification and DDD assignment 2006: Guidelines for ATC classification and DDD assignment 2007: Guidelines for ATC classification and DDD assignment 2008: Guidelines for ATC classification and DDD assignment 2009: Guidelines for ATC classification and DDD assignment 2010: Guidelines for ATC classification and DDD assignment 2011: Guidelines for ATC classification and DDD assignment 2012: Guidelines for ATC classification and DDD assignment 2013: Guidelines for ATC classification and DDD assignment 2014: Guidelines for ATC classification and DDD assignment 2015: Guidelines for ATC classification and DDD assignment 2016: Guidelines for ATC classification and DDD assignment 2017: Guidelines for ATC classification and DDD assignment 1) A co-publication between the WHO Collaborating Centre for Drug Statistics Methodology and the Nordic Council on Medicines PREFACE The Anatomical Therapeutic Chemical (ATC) classification system and the Defined Daily Dose (DDD) as a measuring unit are recommended by the WHO for drug utilization monitoring and research . The system is widely used internationally and the number of users is increasing. The purpose of preparing guidelines is to make information about the ATC/DDD system available to the users. The members of the WHO International Working Group for Drug Statistics Methodology have given expert advice and comments on the work with these guidelines. This edition of the Guidelines for ATC classification and DDD assignment is based on the ATC classification index with DDDs valid from January 2018. The guidelines consist of a general part including information about the procedures and data requirements for ATC/DDD assignment and alterations. The second part of the publication, the interpretative guidelines, describes the different ATC levels down to the 4th level. These guidelines should be consulted whenever the ATC/DDD system is used for drug utilization monitoring and research. They describe particular issues, which have been discussed and resolved by consensus of the Working Group. The Guidelines and the ATC index with DDDs are updated annually. Both publications can be ordered as electronic or paper copies (English or Spanish versions) from the Centre (order form, see website www.whocc.no). A pdf document of the Guidelines and a searchable version of the ATC/DDD index linked to the text from the Guidelines are available on the website (ATC/DDD index). We hope this book will prove helpful to the users of the ATC/DDD system. Suggested improvements can be addressed to the WHO Centre in Oslo. Oslo, December 2017 Hanne Strøm Director WHO Collaborating Centre for Drug Statistics Methodology Norwegian Institute of Public Health Staff of the Centre Christian Berg, MScPharm/MPH Hege Salvesen Blix, MScPharm/PhD Irene Litleskare, MScPharm Marit Rønning, MScPharm Solveig Sakshaug, MScPharm Hanne Strøm, MScPharm Tove Granum, secretary TABLE OF CONTENTS I. Introduction ............................................................................................10 A. History of the ATC/DDD system ....................................................10 B. Present Organizational responsibility for the ATC/DDD system ...10 1. WHO Collaborating Centre for Drug Statistics Methodology ..10 2. WHO International Working Group for Drug Statistics Methodology ..............................................................................11 C. The purpose of the ATC/DDD system ............................................13 II. The anatomical therapeutic chemical (ATC) classification system ..14 A. Structure and nomenclature .............................................................14 B. Inclusion and exclusion criteria .......................................................15 C. Principles for classification .............................................................16 1. Therapeutic use or pharmacological class .................................16 2. Only one ATC code for each route of administration ...............16 3. More than one ATC code for a medicinal substance .................17 4. New ATC groups and “other” groups (X groups) .....................17 5. Other general principles .............................................................18 D. Classification of combination products ...........................................18 E. Principles for changing ATC codes .................................................20 F. The EphMRA classification system ................................................21 III. DDD (Defined Daily Dose) ....................................................................22 A. Definition and general considerations .............................................22 B. Principles for DDD assignment .......................................................23 1. General principles ......................................................................23 2. Combination products ................................................................25 3. Other factors ...............................................................................26 a) Fixed doses ................................................................................26 b) Depot formulations ....................................................................26 c) Intermittent dosing .....................................................................26 d) Duration of treatment ................................................................26 4. Selection of units ........................................................................27 7 C. Pediatric DDD .................................................................................28 D. Principles for reviewing and changing DDD ..................................28 E. Description of other drug utilization metrics ..................................30 IV. Uses of the ATC/DDD methodology .....................................................31 A Implementation and maintenance of the ATC/DDD methodology 31 B. Drug utilization ................................................................................32 1. Data sources ...............................................................................33 2. DDD indicators and interpretations ...........................................34 C. Drug Safety Assessment ..................................................................36 D. Drug information .............................................................................36 E. Drug costs, pricing, reimbursement and cost-containment .............37 F. Pharmaceutical marketing purposes ................................................38 V. Procedures and data requirements for ATC/DDD assignment and alterations ...............................................................................................38 A. Requests for ATC classification ......................................................38 1. Procedures and timing ................................................................38 2. Data requirements for submission .............................................40 B. Requests for ATC changes ..............................................................41 1. Procedures and timing ................................................................41 2. Data requirements for submission .............................................42 C. Requests for DDD assignment ........................................................42 1. Procedures and timing ................................................................42 2. Data requirements for submission .............................................43 D. Requests for DDD changes..............................................................44 1. Procedures and timing ................................................................44 2. Data requirements for submission .............................................44 VI. Description of ATC index with DDDs ..................................................45 VII. Other ATC classification systems ........................................................46 A. ATCvet classification ......................................................................46 B. ATC herbal classification
Load more

Recommended publications
  • Clinical Study Is Nonmicronized Diosmin 600Mg As Effective As
    Hindawi International Journal of Vascular Medicine Volume 2020, Article ID 4237204, 9 pages https://doi.org/10.1155/2020/4237204 Clinical Study Is Nonmicronized Diosmin 600mg as Effective as Micronized Diosmin 900mg plus Hesperidin 100mg on Chronic Venous Disease Symptoms? Results of a Noninferiority Study Marcio Steinbruch,1 Carlos Nunes,2 Romualdo Gama,3 Renato Kaufman,4 Gustavo Gama,5 Mendel Suchmacher Neto,6 Rafael Nigri,7 Natasha Cytrynbaum,8 Lisa Brauer Oliveira,9 Isabelle Bertaina,10 François Verrière,10 and Mauro Geller 3,6,9 1Hospital Albert Einstein (São Paulo-Brasil), R. Mauricio F Klabin 357/17, Vila Mariana, SP, Brazil 04120-020 2Instituto de Pós-Graduação Médica Carlos Chagas-Fundação Educacional Serra dos Órgãos-UNIFESO (Rio de Janeiro/Teresópolis- Brasil), Av. Alberto Torres 111, Teresópolis, RJ, Brazil 25964-004 3Fundação Educacional Serra dos Órgãos-UNIFESO (Teresópolis-Brasil), Av. Alberto Torres 111, Teresópolis, RJ, Brazil 25964-004 4Faculdade de Ciências Médicas, Universidade Estadual do Rio de Janeiro (UERJ) (Rio de Janeiro-Brazil), Av. N. Sra. De Copacapana, 664/206, Rio de Janeiro, RJ, Brazil 22050-903 5Fundação Educacional Serra dos Órgãos-UNIFESO (Teresópolis-Brasil), Rua Prefeito Sebastião Teixeira 400/504-1, Rio de Janeiro, RJ, Brazil 25953-200 6Instituto de Pós-Graduação Médica Carlos Chagas (Rio de Janeiro-Brazil), R. General Canabarro 68/902, Rio de Janeiro, RJ, Brazil 20271-200 7Department of Medicine, Rutgers New Jersey Medical School-USA, 185 S Orange Ave., Newark, NJ 07103, USA 8Hospital Universitário Pedro Ernesto, Universidade Estadual do Rio de Janeiro (UERJ) (Rio de Janeiro-Brazil), R. Hilário de Gouveia, 87/801, Rio de Janeiro, RJ, Brazil 22040-020 9Universidade Federal do Rio de Janeiro (UFRJ) (Rio de Janeiro-Brazil), Av.
    [Show full text]
  • WHO Drug Information Vol. 12, No. 3, 1998
    WHO DRUG INFORMATION VOLUME 12 NUMBER 3 • 1998 RECOMMENDED INN LIST 40 INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES WORLD HEALTH ORGANIZATION • GENEVA Volume 12, Number 3, 1998 World Health Organization, Geneva WHO Drug Information Contents Seratrodast and hepatic dysfunction 146 Meloxicam safety similar to other NSAIDs 147 Proxibarbal withdrawn from the market 147 General Policy Issues Cholestin an unapproved drug 147 Vigabatrin and visual defects 147 Starting materials for pharmaceutical products: safety concerns 129 Glycerol contaminated with diethylene glycol 129 ATC/DDD Classification (final) 148 Pharmaceutical excipients: certificates of analysis and vendor qualification 130 ATC/DDD Classification Quality assurance and supply of starting (temporary) 150 materials 132 Implementation of vendor certification 134 Control and safe trade in starting materials Essential Drugs for pharmaceuticals: recommendations 134 WHO Model Formulary: Immunosuppressives, antineoplastics and drugs used in palliative care Reports on Individual Drugs Immunosuppresive drugs 153 Tamoxifen in the prevention and treatment Azathioprine 153 of breast cancer 136 Ciclosporin 154 Selective serotonin re-uptake inhibitors and Cytotoxic drugs 154 withdrawal reactions 136 Asparaginase 157 Triclabendazole and fascioliasis 138 Bleomycin 157 Calcium folinate 157 Chlormethine 158 Current Topics Cisplatin 158 Reverse transcriptase activity in vaccines 140 Cyclophosphamide 158 Consumer protection and herbal remedies 141 Cytarabine 159 Indiscriminate antibiotic
    [Show full text]
  • Extended-Release 30 Mcg Capsules Service Request Form Fax: 1-844-660-7083 | Phone: 1-844-414-Opko (6756) E-Mail: [email protected]
    RAYALDEE® (CALCIFEDIOL) EXTENDED-RELEASE 30 MCG CAPSULES SERVICE REQUEST FORM FAX: 1-844-660-7083 | PHONE: 1-844-414-OPKO (6756) E-MAIL: [email protected] 1. Patient Information Please complete all fields to prevent any delays. New start to Rayaldee® therapy Existing patient on therapy E-mail Address: Preferred Method of Contact: Cell Phone Home Phone Email Text First Name Last Name SS # (Last 4 only) Preferred Time of Contact: Morning Afternoon Evening Male Female Ok to leave a message: Yes No Date of Birth (MM/DD/YYYY) Primary Language: English Spanish Other:________________________________ 2. Patient Insurance Information Address Attached is a copy of both sides of the patient's insurance card City State ZIP Primary Insurance Phone # Cell Phone Home Phone Policy Holder Name Relationship to Patient Alternate Contact or Healthcare Proxy First Name, Last Name and Phone Insurance ID # Group # 3. Patient Clinical Information Please include supporting clinical documentation. ● ICD-10 Code: ● Lab Values & dates: Please check box 1. or 2. below 25(OH)D__________|__________ Calcium__________|__________ (N18.3) CKD stage 3, (N25.81) Secondary hyperparathyroidism, and 1. value date value date (E55.9) Vitamin D deficiency 2. (N18.4) CKD stage 4, (N25.81) Secondary hyperparathyroidism, and (E55.9) Vitamin D deficiency ● Therapies within the previous 6 months: No previous therapies Hectorol® (doxercalciferol) Rocaltrol® (calcitriol) OTC Vitamin D2 ® OTC Vitamin D3 Prescription Vitamin D2 (ergocalciferol) Zemplar (paricalcitol) 4. Prescriber Information Specialty of Prescriber: Nephrologist PCP Endocrinologist Internist First Name Last Name Phone Fax Practice Name Oce Contact Preferred Time of Contact Address NPI # City State ZIP 5.
    [Show full text]
  • MASCC/ESMO ANTIEMETIC GUIDELINE 2016 with Updates in 2019
    1 ANTIEMETIC GUIDELINES: MASCC/ESMO MASCC/ESMO ANTIEMETIC GUIDELINE 2016 With Updates in 2019 Organizing and Overall Meeting Chairs: Matti Aapro, MD Richard J. Gralla, MD Jørn Herrstedt, MD, DMSci Alex Molassiotis, RN, PhD Fausto Roila, MD © Multinational Association of Supportive Care in CancerTM All rights reserved worldwide. 2 ANTIEMETIC GUIDELINES: MASCC/ESMO These slides are provided to all by the Multinational Association of Supportive Care in Cancer and can be used freely, provided no changes are made and the MASCC and ESMO logos, as well as date of the information are retained. For questions please contact: Matti Aapro at [email protected] Chair, MASCC Antiemetic Study Group or Alex Molassiotis at [email protected] Past Chair, MASCC Antiemetic Study Group 3 ANTIEMETIC GUIDELINES: MASCC/ESMO Consensus A few comments on this guideline set: • This set of guideline slides represents the latest edition of the guideline process. • This set of slides has been endorsed by the MASCC Antiemetic Guideline Committee and ESMO Guideline Committee. • The guidelines are based on the votes of the panel at the Copenhagen Consensus Conference on Antiemetic Therapy, June 2015. • Latest version: March 2016, with updates in 2019. 4 ANTIEMETIC GUIDELINES: MASCC/ESMO Changes: The Steering Committee has clarified some points: 2016: • A footnote clarified that aprepitant 165 mg is approved by regulatory authorities in some parts of the world ( although no randomised clinical trial has investigated this dose ). Thus use of aprepitant 80 mg in the delayed phase is only for those cases where aprepitant 125 mg is used on day 1. • A probable modification in pediatric guidelines based on the recent Cochrane meta-analysis is indicated.
    [Show full text]
  • Par Drugs and Chemicals Limited
    +91-8048372739 PAR DRUGS AND CHEMICALS LIMITED https://www.indiamart.com/pardrugs/ We are one of the leading Manufacturer of various Inorganic Molecules such as-Magnesium Hydroxide, Aluminium Hydroxide, Magnesium & Aluminum Silicates as well the blends of these molecules such as Magaldrate, Almagate, Hydrotalcite etc. About Us Par Drugs & Chemicals Private Limited incorporated in the year 1982 and proved its competency as the known Manufacturer of various Inorganice Molecules such as- Magnesium Hydroxide, Aluminium Hydroxide, Magnesium Trisilicate, Magnesium & Aluminum Silicates as well the blends of these molecules such as Magaldrate, Almagate, Hydrotalcite etcs. Our products stand high in terms of quality and low whereas price is concerned. Mr. F. V. Savani (Marketing Director) has enabled us to gain prominent position in industry. He ensures that the customer’s needs are efficiently fulfilled in an appropriate manner and they are served as per their demands. We do not compromises in terms of quality of our range and ensure that the customers are served accordingly. Our team ensures that products are manufactured in confirmation with the specific quality standards. Packaging of our range is done carefully so that products may reach the clients end in safe manner. Regular training sessions keep our employees aware of the changes taking place in industry and ensure that they also perform accordingly. Our well-equipped infrastructure has enabled us to carry our business operations in smooth and efficient manner. We have efficiently segregated
    [Show full text]
  • Clinical Practice Guideline for Emergency Department Ketamine Dissociative Sedation: 2011 Update
    PAIN MANAGEMENT/CONCEPTS Clinical Practice Guideline for Emergency Department Ketamine Dissociative Sedation: 2011 Update Steven M. Green, MD, Mark G. Roback, MD, Robert M. Kennedy, MD, Baruch Krauss, MD, EdM From the Department of Emergency Medicine, Loma Linda University Medical Center and Children’s Hospital, Loma Linda, CA (Green); the Department of Pediatrics, University of Minnesota, Minneapolis, MN (Roback); the Division of Emergency Medicine, St. Louis Children’s Hospital, Washington University, St. Louis, MO (Kennedy); and the Division of Emergency Medicine, Children’s Hospital Boston and Department of Pediatrics, Harvard Medical School, Boston, MA (Krauss). We update an evidence-based clinical practice guideline for the administration of the dissociative agent ketamine for emergency department procedural sedation and analgesia. Substantial new research warrants revision of the widely disseminated 2004 guideline, particularly with respect to contraindications, age recommendations, potential neurotoxicity, and the role of coadministered anticholinergics and benzodiazepines. We critically discuss indications, contraindications, personnel requirements, monitoring, dosing, coadministered medications, recovery issues, and future research questions for ketamine dissociative sedation. [Ann Emerg Med. 2011;xx:xxx.] 0196-0644/$-see front matter Copyright © 2011 by the American College of Emergency Physicians. doi:10.1016/j.annemergmed.2010.11.030 INTRODUCTION thalamocortical and limbic systems, effectively dissociating the The dissociative
    [Show full text]
  • Antipyretic Efficacy of an Initial 30-Mg/Kg Loading Dose of Acetaminophen Versus a 15-Mg/Kg Maintenance Dose
    Antipyretic Efficacy of an Initial 30-mg/kg Loading Dose of Acetaminophen Versus a 15-mg/kg Maintenance Dose Jean Marc Tre´luyer, MD, PhD*; Sylvie Tonnelier, PharmD*; Philippe d’Athis‡; Beatrice Leclerc§; Isabelle Jolivet-Landreau, MD§; and Ge´rard Pons, MD, PhD* ABSTRACT. Objective. To compare the antipyretic comfort.1 Among the available antipyretic agents, efficacy of an initial 30-mg/kg acetaminophen loading acetaminophen is one of the most widely used be- dose versus a 15-mg/kg maintenance dose. cause it has an antipyretic efficacy equivalent to the Methods. A double-blind, parallel-group, random- other antipyretic drugs and a good safety profile.2–4 ized clinical trial was conducted. A total of 121 febrile Acetaminophen antipyretic efficacy is dose-depen- (rectal temperature between 39°C and 40°C) but other- dent.5,6 The recommended dose is 15 mg/kg every 6 wise healthy outpatients who were 4 months to 9 years of 2 age and weighed 4 to 26 kg were assigned randomly to 1 hours. Following this dosing schedule, it usually -takes several hours after the first acetaminophen ad ؍ and 30 mg/kg (n (62 ؍ of the dose groups: 15 mg/kg (n 59). ministration to obtain the maximal clinical efficacy of Results. In an “intention to treat” analysis, the time to the drug.7 Therefore, Mahar et al8 suggested a phys- obtain a temperature lower than 38.5°C was significantly ical “cold therapy” at the initiation of the chemical shorter in the 30-mg/kg than in the 15-mg/kg group treatment to decrease the time course to antipyretic minutes vs 139 ؎ 113 minutes).
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Clinical Report—Fever and Antipyretic Use in Children Abstract
    Guidance for the Clinician in Rendering Pediatric Care Clinical Report—Fever and Antipyretic Use in Children Janice E. Sullivan, MD, Henry C. Farrar, MD, and the abstract SECTION ON CLINICAL PHARMACOLOGY AND THERAPEUTICS, and COMMITTEE ON DRUGS Fever in a child is one of the most common clinical symptoms managed by pediatricians and other health care providers and a frequent cause KEY WORDS fever, antipyretics, children of parental concern. Many parents administer antipyretics even when ABBREVIATIONS there is minimal or no fever, because they are concerned that the child NSAID—nonsteroidal anti-inflammatory drug must maintain a “normal” temperature. Fever, however, is not the The guidance in this report does not indicate an exclusive primary illness but is a physiologic mechanism that has beneficial course of treatment or serve as a standard of medical care. effects in fighting infection. There is no evidence that fever itself wors- Variations, taking into account individual circumstances, may be ens the course of an illness or that it causes long-term neurologic appropriate. complications. Thus, the primary goal of treating the febrile child This document is copyrighted and is property of the American Academy of Pediatrics and its Board of Directors. All authors should be to improve the child’s overall comfort rather than focus on have filed conflict of interest statements with the American the normalization of body temperature. When counseling the parents Academy of Pediatrics. Any conflicts have been resolved through or caregivers of a febrile child, the general well-being of the child, the a process approved by the Board of Directors.
    [Show full text]
  • Summary of Product Characteristics
    Health Products Regulatory Authority Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Audaval 0.1% Ointment 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One gram of ointment contains 1 mg of betamethasone (0.1% w/w) as valerate. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Ointment Opaque ointment. 4 CLINICAL PARTICULARS 4.1 Therapeutic Indications Audaval preparations are indicated for the treatment of: eczema in children over 1 year elderly and adults; including atopic and discoid eczemas; prurigo nodularis; psoriasis (excluding widespread plaque psoriasis); neurodermatoses, including lichen simplex, lichen planus; seborrhoeic dermatitis; contact sensitivity reactions; discoid lupus erythematosus and they may be used as an adjunct to systemic steroid therapy in generalised erythroderma. In general, ointment preparations are particularly appropriate for dry, lichenified or scaly skin conditions whereas a cream preparation may be more suitable in the case of moist or weeping lesions. 4.2 Posology and method of administration For topical use only. If no improvement is seen after two to four weeks, the diagnosis should be reconsidered and specialist referral may be necessary. Adults, adolescents and the elderly A small quantity of Audaval should be applied to the affected area one to three times daily as directed by physician until improvement occurs. It may then be possible to maintain improvement by applying once a day, or even less often, or by using the appropriate ready diluted (1 in 4) preparation, Audaval RD 0.025% Ointment. Allow adequate time for absorption after each application before applying an emollient. If no improvement is seen within two to four weeks, reassessment of the diagnosis, or referral, may be necessary.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20050181041A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0181041 A1 Goldman (43) Pub. Date: Aug. 18, 2005 (54) METHOD OF PREPARATION OF MIXED Related US. Application Data PHASE CO-CRYSTALS WITH ACTIVE AGENTS (60) Provisional application No. 60/528,232, ?led on Dec. 9, 2003. Provisional application No. 60/559,862, ?led (75) Inventor: David Goldman, Portland, CT (US) on Apr. 6, 2004. Correspondence Address: Publication Classi?cation LEYDIG VOIT & MAYER, LTD (51) Int. Cl.7 ....................... .. A61K 31/56; A61K 38/00; TWO PRUDENTIAL PLAZA, SUITE 4900 A61K 9/64 180 NORTH STETSON AVENUE (52) US. Cl. ............................ .. 424/456; 514/179; 514/2; CHICAGO, IL 60601-6780 (US) 514/221 (73) Assignee: MedCrystalForms, LLC, Hunt Valley, (57) ABSTRACT MD This invention pertains to a method of preparing mixed phase co-crystals of active agents With one or more materials (21) Appl. No.: 11/008,034 that alloWs the modi?cation of the active agent to a neW physical/crystal form With unique properties useful for the delivery of the active agent, as Well as compositions com (22) Filed: Dec. 9, 2004 prising the mixed phase co-crystals. Patent Application Publication Aug. 18, 2005 Sheet 1 0f 8 US 2005/0181041 A1 FIG. 1a 214.70°C z.m."m.n... 206.98°C n..0ao 142 OJ/g as:20m=3: -0.8 -1.0 40 90 1:10 2110 Temperture (°C) FIG. 1b 0.01 as:22“.Km: 217 095 24221.4 39Jmum/Q -0.8 35 155 255 255 Temperture (°C) Patent Application Publication Aug.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]